Location
United States, North America
Cheque size
$50K - $150M
Investment Stage
Series A
Series B
Focus Areas
BioTech
Pharmaceuticals
About Investor
Steven Gillis is a Managing Director at ARCH Venture Partners. He focuses on life sciences, especially biotech and pharmaceuticals, and is most associated with Series A through Series B company-building (while operating across a wider set of rounds as needed). His stated investment range is $50K - $150.0M (sweet spot: $25.0M). His background includes founding and leading biotech companies (including executive leadership roles at Corixa and Immunex) and serving on multiple biotech and pharma boards.
Previous investments
Be Biopharma
92M |2025
130M |2022
EGenesis
190M |2024
130M |2021
100M |2019
38M |2017
Vilya
21M |2024
50M |2022
Similar Investors
AL
Abdul Ly
United States, North America
$1M - $4M
Seed
,Series A
,PS
Paul Straub
United States, North America
$100K - $2M
Pre Seed
,Seed
,RF
Riley Florsheim
United States, North America
$100K - $5M
Pre Seed
,Seed
,DG
Danielle Graham
Canada, North America
$100K - $300K
Pre Seed
,Seed
,JR
JJ Richa
United States, North America
$50K - $1M
Pre Seed
,Seed
,NS
Nikhil Shah
United States, North America
$5K - $50K
Seed
,Series A
,Is this Your Profile?
If you have any updates, please fill out our form.